Hot Life Science Investor Mandate 1: Venture Fund/Family Office Seeking Medical Devices and CLIA Lab Diagnostic Investments

A venture fund/family office founded in 2002 and based in the southern USA manages two venture funds, in addition to a number of private capital accounts through which investments are made. The firm looks to make equity investments generally in series A and B rounds of approximately $1.0 – $1.5 million in rounds totaling $3-$7 million. The firm is open to investing into companies located throughout the United States and makes approximately 2-4 new investments per year.

Within life sciences, the firm is most interested in companies in the medical device and diagnostics space. The firm is looking for companies that have a 510k regulatory pathway with at least a working prototype of the product and preferably some in-human data. The firm is generally open to all indications with particular interested in oncology, rare cancers, diabetes, neurology, ophthalmology and cardiology. The firm is especially interested in CLIA lab diagnostics, software enabled devices, molecular diagnostics for rare cancers and diseases, and algorithms that interpret genetic information and recommend treatment options. The firm is also interested in nutraceuticals, expedited drug development, HIT and business to business technology companies although these areas are less of a focus.

The firm is looking for private companies with experienced management team and looks to take a board seat following investment. The firm looks to be a hands on investor and is willing to both lead and co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 2: Russian Corporate VC Fund Seeking Life Science Investments Globally

A venture capital fund financed entirely by a Russian pharmaceutical company is looking to make investments ranging from $5-$15 million in companies in the life science space. The firm could make as many as 2-3 investment over the next 6-9 months and is willing to allocate to companies located around the globe. Besides equity investment, the firm would consider local licensing opportunities for Russian/CIS market.

The fund is currently looking for companies developing therapeutics and is open to both small molecules, biologics, and cell/gene therapy. The firm is more interested in companies working with single assets although they are also willing to consider platform technologies. Indications of interest include Oncology, Inflammation, Neurodegenerative diseases, Orphan genetic diseases, Critical care, Regenerative medicine and Autoimmune diseases. The firm looks for companies that have at least reached in-vivo proof of concept with their lead asset.

The fund is looking for privately held companies and prefers companies with experienced management teams in place. The firm looks to act as a value-added investor through their strategic alignment with its parent company, and looks to take a seat on the company’s board on a case by case basis. The firm is willing to both lead and co-invest in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 3: Large Chinese VC Fund Seeking Early Stage Cross Border Life Science Investments

A venture capital firm based in Hong Kong has approximately USD 1 billion AUM and has raised 3 funds to date. The firm’s third fund was closed at USD 100 million in 2014. The firm makes early stage investments, typically in series A and B at USD 2-10 million, in the TMT and healthcare sector. The firm’s primary geographic focus is China and Asia, with a growing interest in cross-border opportunities in the US and EU.

In healthcare, the firm is interested in healthcare services, medical devices, early stage therapeutics, and specialty pharma. Within medical devices, the firm seeks growth stage products from MRI to IVD. Within therapeutics, the firm considers both small molecules and biologics. The firm is opportunistic in terms of subsectors and indications. The firm is interested in post-angel stage companies with products that are in pre-clinical or early clinical trials. Later stage opportunities can also be considered.

The firm seeks a strong and experienced management team and could act as lead investor or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 4: Joint Venture Investment Company Seeking Companies with Digital Tech Innovation in Life Sciences

A joint venture investment company was launched in January 2015 by a large pharmaceutical company and a large technology company. The firm strives to catalyze the success of digital medicine products, services and business models by investing in early-stage companies and leveraging its extensive networks in Pharma, Mobile/IT, and investment community. The firm expects to make equity investments of up to $5 million per deal. The firm is currently seeking opportunities in the US, EU, and Australia where healthcare systems are more mature.

The firm is seeking entrepreneurs using digital technology to transform pharmaceutical products, sales and marketing, R&D, and enterprise operations. Examples may include enterprise software solutions that improves clinical care or mobile sensors for disease management in home care settings.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Winning Your Next Stage Investment—One Competition at a Time

By Shaoyu Chang, MD, MPH,  Senior Research Analyst, LSN

Shaoyu 10*10

There’s no shortage of competitions for life science entrepreneurs to enter. Whether it is a grant submission on a website, a display in an exhibition hall, or a 10-minute pitch on stage, there will be opportunities to use your branding and messaging collateral to reach an audience. However, it takes a well-organized package of information to win access to these opportunities.

While screening applicants to the RESI Innovation Challenge, I’ve observed that many companies make similar mistakes. In this article, I’d like to offer some tips for making the most of these opportunities while avoiding common pitfalls.

Explain science in simple, clear language

What factors will make your new product stand out from other “exciting one-of-a-kind therapies”? Entrepreneurs may have the most cutting-edge, complex technology, but many of them fail to describe their science in plain, understandable English. You description should be clear and concise while providing your unique value proposition. Do not be afraid to take a deeper dive in the mechanism behind your invention, what cellular pathway does your compound affect? How does your device work on the target organ? Remember how you deliver your message and explain what you do shows how what a good investment candidate you are.

Instead of making a nonspecific claim, such as “our device has convincing validation,” applicants can make a stronger case by providing supporting facts, such as “our non-invasive device can measure blood pressure within ±3 mmHg error margin” or “data from our small mammal studies has been published in peer-reviewed journals.” Keeping in mind, there should be a balance between being specific and being overwhelmingly technical. It is not easy to fit your full scientific discovery story into the 500-word limit; however that is precisely the challenge you face when you enter the sales and marketing domain and want to raise capital.

Stand out from the crowd

In the early stage life science investment world, many potential scientific breakthroughs are competing for the same pool of funding. It’s important to put yourself in the investor’s position and think about the factors that make your company a unique opportunity to deploy capital.

What factors will make your new product stand out among 20 other “exciting one-of-a-kind therapies”? It could be that the product serves a large patient base with a significant unmet medical need. Or perhaps it’s a solution for a niche population that would qualify for orphan status and potentially accelerate your path to market. Other factors that LSN has seen raised by strong contenders in the RESI Innovation Challenge include good patent coverage, cost-saving propositions for healthcare providers, and the potential to save the lives of patients in need. Be sure to state the reasons why your opportunity is outstanding.

Explain the timeline to market

Many entrepreneurs fail to provide a detailed, realistic development timeline. This is a critical element as investors use it to assess entrepreneurs’ understanding of the R&D process in their technology sector and their ability to allocate funding properly.

Highlight your business successes

When providing management team bios, most scientist-entrepreneurs have little difficulty in describing academic credentials, from faculty positions to publication records. However, applicants often neglect the business aspect. Investors want to see a team that is able to work together, negotiate with external partners and next-round investors, and bring the product through the regulatory process. Entrepreneurs should highlight expertise in such areas or set up plans to recruit these experts.

Similarly, collaborative relationships with prestigious research centers, pharmaceutical corporations, or strategic partners act as indicators of endorsement and validation. Don’t forget to highlight these markers of your business acumen.

Make sure your marketing collateral is clear and available

Furthermore, our scientific team looks at the clarity of the application material and also the availability of supporting publications, including on your company’s website, because these materials reflect the overall quality of an entrepreneur’s presentation. Many investors in the life sciences sector are well versed in the industry, and have extensive background knowledge and research skills. A company unable to provide supporting materials online is at risk of being screened out by an investor in the initial stages of the investment process.

Past winners of the RESI Innovation Challenge have demonstrated that a good branding and messaging strategy not only helps entrepreneurs excel in start-up competitions, but also opens doors to partnerships and investments critical to their businesses. If you are interested in showcasing your innovation at RESI, please submit your application here.

RESIIC-wp

Corporate VC Investors Sharing Tips of Their Trade at RESI

By Lucy Parkinson, Senior Research Manager, LSN

lucy 10*10At RESI @ TMCx, LSN turned the spotlight on corporate venture capital for an hour-long panel session. Six experienced corporate venture capitalists explored key issues that they face when engaging with startups. Panelists were asked if their firms invested with the intent to own a company, and what term sheet provisions might make it impossible for a corporate VC to invest. The panel also tackled the thorny question of valuation, and of how early it was possible for them to invest in a biotech company. Finally, the investors spelt out their internal processes and areas of focus, and the means by which they uncover opportunities. If you’re interested in meeting with a corporate VC, be sure to watch this RESI @ TMCx panel video first.

 

RESI-Boston-wp

LSN Summer Reading Series Chapter 10: “Phone Canvassing”

By Michael Quigley, Director of Research, LSN

Once you have a global target list of investors as we outlined in last week’s chapter, you will want to begin going outbound and contacting these groups. With this week’s edition of the summer reading series, we explain what goes into an effective phone canvassing campaign.

“Chapter 10: Phone Canvassing” goes through the process of reaching out to potential investors effectively via the phone. Now the idea of contacting investors, or anyone for that matter, via a cold call may sound daunting to many fundraising entrepreneurs; however, in the highly competitive marketplace for early stage investment, entrepreneurs should use this and all professional tactics available to them in order to separate from the crowd and garner more attention from potential investors.

Click here to download/print the chapter PDF

Join us next week for Chapter 11: “Email Campaigns”

Enjoyed the preview? Buy now from Amazon.com or Barnes & Noble

Bookcover-Front